3.5M
Cases from Neonatal Sepsis
600,000
Deaths
$xx
Per Episode
xx
Infections Resistant to Antibiotics
OUR PURPOSE
"The NeoNET Africa network seeks to address the pressing issue of neonatal deaths due to bacterial infections in sub-Saharan Africa. With a focused multidisciplinary approach, the network aims to consolidate research, foster collaborations, and leverage existing expertise to provide concrete solutions."
Zimbabwean mother and baby at Tygerberg Hospital
7M
Neonatal deaths
each year globally
WHO WE ARE

A network of professionals and families committed to addressing the evidence gap for how we can best identify, treat and prevent neonatal sepsis in the smallest, most vulnerable babies in sub-Saharan Africa. Where you are born should not stop you receiving effective care.

Our work aims to find the best ways to safely reduce unnecessary antibiotic use in babies, prioritising resources for those babies most in need, and the best ways to prevent the spread of infection between babies, even with scarce resources.

Harmonising Data Across Borders

A federated data platform to maximise the data we have while preserving data sovereignty.

Pragmatic Guidelines

Developing best practice guidelines for use in low-resource settings.

WHAT WE DO

Three Pillars of Newborn Care

Newborn with neonatal sepsis

Epidemiology

Data about the bacteria causing neonatal sepsis in sub-Saharan Africa are patchy — we're aiming to change that.

Research laboratory

Research

We will build a platform for researchers across Africa to work together to answer key questions about neonatal sepsis.

Clinical team

Capacity Building

Supporting African microbiologists, doctors, data scientists and families to work together to tackle neonatal sepsis.

Prof. Adrie Bekker and Prof. Angela Dramowski at Tygerberg
NeoSep1 Trial
LANDMARK RESEARCH

The NeoSep1 Trial: Rewriting the Rules of Neonatal Sepsis Treatment

Neonatal sepsis is the third leading cause of newborn death worldwide, yet the antibiotics used to treat it have barely changed in 50 years — and resistance is rising. NeoSep1 is a multi-country adaptive platform trial testing new antibiotic combinations to find better, safer treatments.

Our data infrastructure underpins the trial at sites across Africa and Asia, enabling researchers to recruit patients faster and generate evidence that will directly change treatment guidelines globally.

8+
Trial Sites
5
Countries
1,000+
Participants Enrolled
OUR PEOPLE

Clinicians, Researchers, Champions

Our team spans paediatricians, nurses, data scientists, and global health researchers united by one goal: to stop the spread of antibiotic resistance in babies in sub-Saharan Africa.

Prof. Angela Dramowski
Prof. Angela Dramowski

NeoSep1 Principal Investigator

Paediatric Infectious Diseases specialist at Stellenbosch University & Tygerberg Hospital, and leading voice in neonatal sepsis research across sub-Saharan Africa.

Prof. Adrie Bekker
Prof. Adrie Bekker

Neonatologist & Site Lead

Head of Neonatology at Tygerberg Hospital and Stellenbosch University. Prof. Bekker leads the clinical programme and drives quality improvement in newborn care across the Western Cape.

Nursing team at Tygerberg
Nursing & Clinical Team

The Frontline of Neonatal Care

Dedicated nurses like Zimkhitha Ndinisa are the backbone of our work — using the platform every shift to capture data, follow protocols, and give every baby the very best start in life.

Support the Next Generation of Neonatal Care

Your support helps us deploy in more hospitals, train more healthcare workers, and generate the research evidence that saves lives across Africa and beyond.